Erectile dysfunction （ED） is a common sexual problem affecting up to one-third of men throughout their lives. According to the Massachusetts Male Aging Study （MMAS）, ED affects an estimated 52% of men between the ...Erectile dysfunction （ED） is a common sexual problem affecting up to one-third of men throughout their lives. According to the Massachusetts Male Aging Study （MMAS）, ED affects an estimated 52% of men between the ages of 40 and 70. With the approval of sildenafil （USA in March 1998）, the first phosphodiesterase type 5 （PDE-5） inhibitor to be made available for treatment of ED, and the subsequent approval of vardenafil （USA in August 2003） and tadalafil （USA in November 2003）, the PDE-5 inhibitor class of drugs has rapidly become the first-line therapy for ED of varying etiologies and severities.展开更多
文摘Erectile dysfunction （ED） is a common sexual problem affecting up to one-third of men throughout their lives. According to the Massachusetts Male Aging Study （MMAS）, ED affects an estimated 52% of men between the ages of 40 and 70. With the approval of sildenafil （USA in March 1998）, the first phosphodiesterase type 5 （PDE-5） inhibitor to be made available for treatment of ED, and the subsequent approval of vardenafil （USA in August 2003） and tadalafil （USA in November 2003）, the PDE-5 inhibitor class of drugs has rapidly become the first-line therapy for ED of varying etiologies and severities.
